Home - Calico
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program
News & Media - Calico
Welcome to the Calico media center. Please find below features on our R&D efforts as well as our official press releases. For media inquiries, please email [email protected].
Calico Stories - Calico
Cardiometabolic diseases are an increasing global health burden. And Calico scientists, led by Madeleine Cule, are working with the University of Westminster and … Keep Reading
Collaborator Profiles - Calico
Calico and AbbVie’s Fosigotifator Selected for FDA’s New START Pilot Program Since 2015, Calico and the Broad Institute of MIT and Harvard have partnered to investigate the biology …
Patients - Calico
Calico registers interventional clinical trials conducted in patients on www.clinicaltrials.gov. If you are a patient interested in one of our clinical trials, please visit www.clinicaltrials.gov to learn …
People - Calico
Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore Careers
Drug Development - Calico
Calico Stories December 4, 2023 Probing the entire genome to pinpoint novel immunotherapy targets
Astrid Gillich, Ph.D. - Calico
Prior to Calico, Astrid was a postdoctoral fellow in the lab of Mark Krasnow at Stanford University where she defined the three-dimensional cellular structure of alveoli and discovered a novel …
David Kelley, Ph.D. - Calico
Calico Publications: The genetic and biochemical determinants of mRNA degradation rates in mammals Individual cell types in C. elegans age differently and activate distinct cell-protective …
Wen Lu, Ph.D. - Calico
Before joining Calico, Wen was a postdoctoral scholar in Arthur Weiss’s lab at the University of California, San Francisco, where he investigated T cell development and survival, and the …